



March 18, 2020

**Re: NETSPOT® - Health Canada Approved and Now Available
Kit for the preparation of gallium (⁶⁸Ga) oxodotreotide injection**

Dear Healthcare Professional,

Advanced Accelerator Applications S.A. (AAA), a Novartis company is pleased to announce that Health Canada has approved **NETSPOT®** (*kit for the preparation of gallium (⁶⁸Ga) oxodotreotide injection*).

INDICATION

NETSPOT® [kit for the preparation of gallium (⁶⁸Ga) oxodotreotide injection], after radiolabeling with gallium (⁶⁸Ga), is indicated for use with positron emission tomography (PET), as an adjunct to other diagnostic tests for localization of somatostatin receptor-positive neuroendocrine tumors (NETs).

TO ORDER NETSPOT® (DIN 02490005):

- For ordering support or general questions, please contact AAA Customer Service at Tel: 1-844-367-3222 or send an email to orders-Canada@adacap.com.
- AAA Customer Service is available from 9:00 AM EST to 8:00 PM EST, Monday to Friday.

FOR MORE INFORMATION:

Please consult the Product Monograph at <https://www.adacap.com/our-products/> for important product information relating to dosing information, drug interactions and adverse reactions. The Product Monograph is also available by calling AAA Customer Service at Tel: 1-844-367-3222.

Any issues pertaining to product quality or safety should be immediately reported to AAA Pharmacovigilance at CA-pharmacovigilance@adacap.com.

Regards,

Lyndal Walker

President & General Manager, Canada
Advanced Accelerator Applications, A Novartis Company
Tel: (647) 612-4805
www.adacap.com